Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells

• Published in: Endocrinology (Philadelphia) Vol. 163; no. 2; p. 1
• Main Authors: Abate, Andrea, Rossini, Elisa, Tamburello, Mariangela, Laganà, Marta, Cosentini, Deborah, Grisanti, Salvatore, Fiorentini, Chiara, Tiberio, Guido A M, Scatolini, Maria, Grosso, Enrico, Hantel, Constanze, Memo, Maurizio, Berruti, Alfredo, Sigala, Sandra
• Format: Journal Article
• Language: English
• Published: United States Oxford University Press 01.02.2022
• Subjects: Adrenal Cortex Neoplasms - drug therapy; Adrenal Cortex Neoplasms - pathology; Adrenocortical Carcinoma - drug therapy; Adrenocortical Carcinoma - pathology; Aminopyridines - administration & dosage; Analysis; Antimitotic agents; Antineoplastic agents; Antineoplastic Agents - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Apoptosis; Apoptosis - drug effects; Cancer; Cancer therapies; Carcinoma; Cell culture; Cell Cycle - drug effects; Cell death; Cell growth; Cell Line, Tumor; Cell proliferation; Cell Proliferation - drug effects; Cell Survival - drug effects; Cell viability; Cells, Cultured; Chemotherapy; Cisplatin; Cytotoxicity; Development and progression; Dimethyl sulfoxide; Doxorubicin; Drug approval; Endocrinology; Etoposide; G2 phase; Gene expression; Health aspects; Humans; Immunofluorescence; Mitotane - administration & dosage; Neuroendocrine tumors; Progesterone; Progesterone - administration & dosage; Purines - administration & dosage; Toxicity; CDK4/6-inhibitor; adrenocortical carcinoma; mitotane; ribociclib; progesterone
• ISSN: 0013-7227; 1945-7170
• DOI: 10.1210/endocr/bqab248

Mitotane is the only approved drug for treating adrenocortical carcinoma (ACC). The regimen added to mitotane is chemotherapy with etoposide, doxorubicin, and cisplatin. This pharmacological approach, however, has a limited efficacy and significant toxicity. Target-therapy agents represent a new promising approach to cancer therapy. Among these, a preeminent role is played by agents that interfere with cell-cycle progression, such as CDK4/6-inhibitors. Here, we investigate whether ribociclib could induce a cytotoxic effect both in ACC cell line and patient-derived primary cell cultures, alone or in combined settings. Cell viability was determined by 3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2H-tetrazolium bromide assay, whereas cell proliferation was evaluated by direct count. Binary combination experiments were performed using Chou and Talalay method. Gene expression was analyzed by quantitative RT-PCR, whereas protein expression was evaluated by immunofluorescence. A double staining assay revealed that ribociclib induced a prevalent apoptotic cell death. Cell-cycle analysis was performed to evaluate the effect of ribociclib treatment on cell-cycle progression in ACC cell models. Our results indicate that ribociclib was cytotoxic and reduced the cell proliferation rate. The effect on cell viability was enhanced when ribociclib was combined with progesterone and/or mitotane. The effect of ribociclib on cell-cycle progression revealed a drug-induced cell accumulation in G2 phase. The positive relationship underlined by our results between ribociclib, progesterone, and mitotane strengthen the clinical potential of this combination.